Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy

J Glob Antimicrob Resist. 2021 Dec:27:324-325. doi: 10.1016/j.jgar.2021.09.014. Epub 2021 Nov 12.

Authors

Briony Adams¹, Alec Beaney²

Affiliations

¹ Core Trainee Year 1 (CT1) Acute Care Common Stem (ACCS) Anaesthetics, Musgrove Park Hospital. Electronic address: brionyadams@outlook.com.
² Specialty Registrar Anaesthetics, Stockport NHS Foundation Trust, Stockport, UK.

No abstract available

Keywords: Antimicrobial; Bacterial; COVID-19; Continuous venovenous haemofiltration; Procalcitonin; Renal replacement therapy.

Publication types

Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
COVID-19*
Humans
Procalcitonin*
Renal Replacement Therapy
SARS-CoV-2

Substances

Anti-Bacterial Agents
Procalcitonin